Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA trial) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Kruszewski, M
  • Schmoor, C
  • Berg, Tobias
  • Schittenhelm, M
  • Goetze, K
  • Kuendgen, A
  • Pabst, C
  • Ma, T
  • Frey, A
  • Moschalski, K
  • Rehman, U-U
  • Jung, J
  • Duyster, J
  • Jung, M
  • Schuele, R
  • Waesch, R
  • Grishina, O
  • Lubbert, M

publication date

  • October 3, 2023